Scientific Unit for Clinical and Medical Research, Osijek University Hospital
Abstract
Rak je bubrega neoplazma koja je razmjerno otporna na postojeću kemoterapiju, hormonsko i iradijacijsko liječenje, stoga se u liječenju bolesnika s rakom bubrega primjenjuju i testiraju lijekovi ili terapije s imunomodulatornim djelovanjem. U kliničkoj praksi, a sa svrhom imunoterapije, najčešće se primjenjuju rekombinantni citokini interferon-alfa (INF-a) i interleukin-2 (IL-2). Ta dva citokina mogu izazvati terapijski odgovor u 10% do 30% bolesnika s metastatskim rakom bubrega. Dugoročno preživljenje ipak je rijetko, nešto češće u bolesnika koji su primali visokodozni IL-2. Kako liječenje raka bubrega usprkos brojnim studijama s različitim terapijama nije zadovoljavajuće, u tijeku su i kliničke studije s drugim imunoterapijskim postupcima.Renal cell carcinoma (RCC) is generally resistant to standard chemotherapy, hormonal or irradiation treatments. Therefore, various drugs or therapies with immunomodulatory action were or are tested in kidney cancer patients. In clinical praxis many approaches have been investigated of which interferon-alpha (INF-") and interleukin-2 (IL-2) are the most extensively studied ones. These two cytokines can achieve response rates in 10% to 30% of patients with metastatic RCC. Long-term survival, however, is achieved only in few patients. More frequently in the ones who have been receiving high-dose IL-2. Consequently, the treatment of RCC is far from being optimal. Therefore, other and novel immunotherapeutic strategies are ongoing or planned to be tested in clinical trials
